Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$10.47 ▲ +0.15
(+1.45%)
MKT CAP: $1.73B • VOL: 2.80M
52W L $6 52W H $13
NVAX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.12B | $682.2M | $983.7M |
| YoY Revenue Growth % | +64.7% | -30.7% | — |
| Gross Profit | $1.05B | $479.4M | — |
| Gross Margin % | 93.5% | 70.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $452.8M | -$248.9M | -$566.5M |
| Operating Margin % | 40.3% | -36.5% | -57.6% |
| Net Income (GAAP) | $440.3M | -$187.5M | -$545.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$244.6M | -$87.3M | -$714.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$244.6M | -$87.3M | -$714.0M |
| FCF Margin % | -21.8% | -12.8% | -72.6% |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $240.6M | $530.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$127.8M | -$623.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NVAX.